
CLAIMS

1. Use of a pharmaceutical composition comprising BT8009,



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier selected from a buffering agent, a stabilizer or cryoprotectant, and a surfactant in the manufacture of a medicament for treating an advanced solid tumor malignancy associated with Nectin-4-expression in a human patient, wherein the pharmaceutical composition is to be intravenously administered to the patient once every seven days at a dose of 5 mg/m^2.

2. The use of claim 1, wherein the pharmaceutical composition is to be administered via an IV infusion of 60 minutes.

3. The use of claim 1 or 2, wherein the advanced solid tumor malignancy associated with Nectin-4-expression is selected from the group consisting of non-small-cell lung cancer (NSCLC), ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, pancreatic cancer, and urothelial cancer.

4. The use of any one of claims 1-3, wherein the advanced solid tumor malignancy associated with Nectin-4 expression is urothelial cancer.

5. The use of any one of claims 1-4, wherein the buffering agent is histidine.

6. The use of any one of claims 1-5, wherein the stabilizer or cryoprotectant is sucrose.

7. The use of any one of claims 1-6, wherein the surfactant is Polysorbate 20.

8. The use of any one of claims 1-7, further comprising a pH adjusting agent.

9. The use of claim 8, wherein the pH adjusting agent comprises hydrochloric acid.

10. The use of any one of claims 1 -9, wherein the pharmaceutical composition is a solid pharmaceutical composition in lyophilized powder form.

11. The use of any one of claims 1-9, wherein the pharmaceutical composition is a liquid pharmaceutical composition further comprising water.

12. The use of any one of claims 1-11, comprising:
BT8009, or a pharmaceutically acceptable salt thereof;
1.31-2.62 mg histidine per mg of BT8009, or a pharmaceutically acceptable thereof; 15-30 mg sucrose per mg of BT8009, or a pharmaceutically acceptable thereof; and
0.05-0.1 mg Polysorbate 20 per mg of BT8009, or a pharmaceutically acceptable thereof.

13. The use of claim 12, comprising:
21.2 mg BT8009, or a pharmaceutically acceptable salt thereof;
27.8 mg histidine;
318 mg sucrose; and
1.06 mg Polysorbate 20.

14. The pharmaceutical composition of claim 11, comprising:
2-4 mg/mL BT8009, or a pharmaceutically acceptable salt thereof;
5.24 mg/mL histidine;
60 mg/mL sucrose; and
0.2 mg/mL Polysorbate 20.

15. The use of any one of claims 1-14, further comprising Nivolumab to be administered to the patient.

16. The use of claim 15, wherein the Nivolumab is to be administered via an IV infusion of 30 minutes.